Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

Abstract Background Placebo-controlled clinical trials have demonstrated the efficacy of tocilizumab (TCZ) for remission maintenance and glucocorticoid sparing in patients with giant cell arteritis (GCA). However, limited data exist on the effectiveness and safety of TCZ for GCA in real-world clinic...

Full description

Bibliographic Details
Main Authors: Sebastian Unizony, Timothy J. McCulley, Robert Spiera, Jinglan Pei, Paris N. Sidiropoulos, Jennie H. Best, Christine Birchwood, Andrey Pavlov, John H. Stone
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Arthritis Research & Therapy
Subjects:
Giant cell arteritis
Tocilizumab
Real-world study
Visual manifestations
Polymyalgia rheumatica
Online Access:https://doi.org/10.1186/s13075-020-02377-8

Internet

https://doi.org/10.1186/s13075-020-02377-8

Similar Items